Research Revenue Totalled $0.6 Million in Q3
2018Product Data Science Fellow to Lead Evidence-Based Product
Research via Proprietary, 10M Point Patient Dataset
Aleafia Health Inc. (TSXV: ALEF, OTC: ALEAF, FRA: ARAH)
(“
Aleafia Health” or the
“
Company”), has appointed Dr. Graham Merry, as the
Company’s first Product Data Science Fellow. Leveraging the
Company’s proprietary 10 million point medical cannabis patient
dataset, Dr. Merry will lead Aleafia Health’s ongoing medical
cannabis research. These efforts will be aimed at developing
evidence-based, proprietary treatment methods and products for
chronic illnesses including pain, insomnia, anxiety and eating
disorders.
Aleafia Health generated $0.6 million in research revenue in Q3
2018 alone, fuelled primarily by medical cannabis companies
subscribing to Aleafia Health’s proprietary medical cannabis
patient dataset. Aleafia Health tracks all patient interactions
with referring doctors, nurse practitioners and educators from
diagnosis, treatment, monitoring, and continuous learning. The
highly differentiated medical cannabis patient big data leverages
an enterprise-wide proprietary platform data set on Amazon AWS with
market leading data visualization and business insights tools
powered by Google Data Studio. These tools are uniquely configured
based on over 50,000 unique patients.
Dr. Merry graduated in Medicine from The Royal London
Medical College in London, U.K and is the founder of Photospectra
Health Sciences Inc. which focuses on the research and development
of treatments for Age-related Dry Macular Degeneration, a common
eyesight disorder. He has instigated, been a principal investigator
and published clinical trials internationally.
The appointment of the Product Data Science Fellow is part of a
global initiative by Aleafia Health to build an integrated,
scalable cannabis consumer experience, leveraging the Company’s
in-house, executive leadership experience at multi-billion dollar
eCommerce and IT companies.
“Aleafia Health continues to accelerate our purpose of helping
people live better lives through a unique, scalable cannabis
consumer experience. We will enable patients to navigate seamlessly
through, cannabis education, illness specific questionnaires,
medical cannabis script product purchasing, order subscription
management and treatment/titration monitoring,” said Aleafia Health
CEO Geoffrey Benic. “We look forward to Dr. Merry leading our
research efforts and team and making significant contributions to
evidence based medicine.”
“The medical and research teams at Aleafia Health are extremely
well positioned today with the addition of Dr. Merry. We will
continue to make important contributions to the research of medical
cannabis treatment best practices and product development,” said
Aleafia Chief Medical Officer Dr. Michael Verbora.
Current Aleafia Health research initiatives include an insomnia
study in partnership with Cronos Group, a cannabinoid
pharmacogenetics study with Guided 420 Genetics and U.S. based
AKESOgen, and a recently published study in the journal Cannabis
and Cannabinoid Research on cannabis and benzodiazepines.
“I am very excited to be involved in clinical research helping
Aleafia realize its goals and ambitions to improve the lives of
patients. I have been tremendously impressed with the whole team at
Aleafia while working in this field,” said Dr. Merry. “This
initiative will allow the opportunity to obtain clinical evidence
to validate and gain wider acceptance in the medical community
realizing the benefits of cannabinoid treatment in serious and
debilitating disease. Together we will make a huge difference in
addressing the unmet needs of patients in this emerging field of
medicine.”
Aleafia Health is also pleased to announce the appointment of
Dr. Taylor Lougheed as Physician Lead for QI/QA of Clinic
Operations. Dr. Lougheed has an extensive history in cannabinoid
prescribing as the lead physician at the Canabo Medical Clinic in
Ottawa, and holds a Master’s degree in Healthcare Quality from
Queen’s University. Dr. Lougheed will help drive efficiencies
across a growing clinic network and leverage Aleafia proprietary
research data to optimize clinical decision making to maximize
cannabinoid therapy outcomes for patients.
LEARN MORE: http://www.aleafiainc.com/Invest
For Investor & Media Relations, please
contact:
Nicholas Bergamini, VP, Public
Affairs416-860-5665IR@AleafiaInc.com
About Aleafia Health:
Aleafia, a vertically integrated, national cannabis company,
operates major medical clinic, cannabis cultivation and R&D
facilities. A federally licensed producer and vendor of cannabis,
the company has a planned and fully-funded annual production
capacity of 98,000 kg of dried cannabis flower.
Aleafia operates medical cannabis clinics staffed by physicians
and nurse practitioners, with over 50,000 patients. The company is
highly differentiated, maintaining the largest medical cannabis
dataset in the world.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements and
information that are based on the beliefs of management and reflect
the Company's current expectations. When used in this press
release, the words "estimate", "project", "belief", "anticipate",
"intend", "expect", "plan", "predict", "may" or "should" and the
negative of these words or such variations thereon or comparable
terminology are intended to identify forward-looking statements and
information.
The forward-looking statements and information in this press
release includes information relating to the implementation of
Aleafia Health's business plan. Such statements and information
reflect the current view of the Company with respect to risks and
uncertainties that may cause actual results to differ materially
from those contemplated in those forward-looking statements and
information.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause our
actual results, performance or achievements, or other future
events, to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among others, the
following risks: risks associated with the implementation of
Aleafia Health's business plan and matters relating thereto, risks
associated with the cannabis industry, competition, regulatory
change, the need for additional financing, reliance on key
personnel, the potential for conflicts of interest among certain
officers or directors, and the volatility of the Company's common
share price and volume. Forward-looking statements are made based
on management's beliefs, estimates and opinions on the date that
statements are made, and the Company undertakes no obligation to
update forward-looking statements if these beliefs, estimates and
opinions or other circumstances should change. Investors are
cautioned against attributing undue certainty to forward-looking
statements.
A photo accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/77350ddb-f7b5-401e-944a-fce349e54a60
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From Jul 2023 to Jul 2024